Exabis Library:

Welcome to the e-CCO Library!

Search by:

All Congress AbstractsCongress SlidesTools & SkillsVideos & Podcasts

Year: Category:

DOP030: Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study

Year: 2016

Source: ECCO'16 DOP

Authors: Smits L.

anti-TNF, biosimilars, infliximab, real world data

Files: 1

DOP030: The efficacy of home telemonitoring versus conventional follow-up: A randomised controlled trial among teenagers with Inflammatory Bowel Disease

Year: 2018

Source: ECCO'18 Vienna

Authors: Van Rheenen Patrick

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP030: The efficacy of home telemonitoring vs. conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel disease

Year: 2018

Source: ECCO '18 Vienna

Authors:

A. Heida¹, A. Muller Kobold², J. Rossen³, A. Kindermann⁴, F. Kokke⁵, T. Meij, De⁶, O. Norbruis⁷, R. Weersma⁸, M. Wessels⁹, T. Hummel¹⁰, H. Escher¹¹, H. Wering, van¹², D. Hendriks¹³, L. Mearin¹⁴, H. Groen¹⁵, H. Verkade¹, P. Van Rheenen¹*

Created: Thursday, 21 February 2019, 9:14 AM

DOP031: Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis – data from two Central European countries

Year: 2016

Source: ECCO'16 DOP

Authors: Bor R.

anti-TNF, biosimilars, infliximab, real world data, mucosal healing

Files: 1

DOP031: Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis: data from 2 Central European countries

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

K. Farkas¹, M. Rutka¹, P.A. Golovics², Z. Végh², B.D. Lovász², T. Nyári³, K.B. Gecse², M. Kolar^{4, 5}, M. Bortlik^{4, 6}, D. Duricova^{4, 7}, N. Machkova⁴, V. Hruba⁴, M. Lukas⁴, K. Mitrova^{4, 8}, K. Malickova⁹, A. Bálint¹, F. Nagy¹, R. Bor*¹, A. Milassin¹, Z. Szepes¹, K. Palatka¹⁰, P.L. Lakatos², M. Lukas^{4, 9}, T. Molnár¹

Created: Friday, 22 February 2019, 9:49 AM

DOP031: Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice

Year: 2018

Source: ECCO '18 Vienna

Authors:

D.V. Ankersen*, D. Marker, P. Weimers, J. Burisch, P. Munkholm

Created: Thursday, 21 February 2019, 9:14 AM

DOP031: Individualized home-monitoring of disease activity in adult patients with Inflammatory Bowel Disease can be recommended implemented in clinical practice

Year: 2018

Source: ECCO'18 Vienna

Authors: Ankersen Dorit Vedel

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP031: Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in paediatric Crohn's disease patients

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Kang B.^*1, Lee K.¹, Kim K.², Lee J.H.³, Choe Y.H.¹

Created: Wednesday, 20 February 2019, 10:36 AM

Year: 2017

Source: ECCO'17 Barcelona

Authors: Kang B.

Anti-TNF drug levels, Colonoscopy, Infliximab, Pharmacokinetics, Thiopurines (AZA / MP)

Files: 1

DOP032: 28Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe

Year: 2016

Source: ECCO'16 DOP

Authors: Kolar M.

anti-TNF, biosimilars, infliximab, real world data

Files: 1

DOP032: Crohn’s disease patients’ perspectives towards de-escalating immunosuppressive therapy: a comparative French and American survey

Year: 2018

Source: ECCO '18 Vienna

Authors:

C.A. Siegel¹*, K.D. Thompson², D. Walls³, J. Gollins⁴, A. Buisson⁵, A. Olympie⁵, L. Beaugerie⁶, J.-F. Colombel⁷, E. Louis on behalf of the BIOCYCLE group⁸

Created: Thursday, 21 February 2019, 9:14 AM

DOP032: Crohn’s Disease patients’ perspectives towards de-escalating immunosuppressive therapy: A comparative French and American survey

Year: 2018

Source: ECCO'18 Vienna

Authors: Siegel Corey A.

Created: Tuesday, 8 May 2018, 11:36 AM

Files: 1

DOP032: Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: clinical and pharmacokinetic outcomes

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Tran-Minh M.-L.^*1, Maillet M.¹, Auzolle C.^1,2, Simon M.³, Cathala A.L.¹, Aparicio T.^1,2, Baudry C.¹, Bonnet J.¹, Lourenco N.¹, Houze P.⁴, Gornet J.-M.¹, Allez M.^1,2

Created: Wednesday, 20 February 2019, 10:36 AM

DOP032: Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: Clinical and pharmacokinetic outcomes

Year: 2017

Source: ECCO'17 Barcelona

Authors: Tran-Minh M.

Anti-TNF drug levels, Anti-drug antibodies, Anti-TNF agents, Infliximab

Files: 1

DOP032: Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

M. Kolar*¹, D. Duricová², M. Brotlik¹, V. Hruba¹, N. Machkova¹, K. Mitrova¹, K. Malickova³, M. Lukas¹, M. Lukas¹

Created: Friday, 22 February 2019, 9:49 AM

DOP033: Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort

Year: 2016

Source: ECCO'16 DOP

Authors: Lovasz B.

anti-TNF, biosimilars, infliximab, real world data, anti-TNF drug levels, anti drug antibodies

Files: 1

DOP033: Immunogenicity profile and predictors of TLs and ADA development of biosimilar infliximab during the first 6 months of the therapy: results from a prospective nationwide cohort

Year: 2016

Source: ECCO '16 Amsterdam

Authors:

B. Lovasz*¹, Z. Kurti¹, M. Rutka², Z. Vegh¹, K. Gecse¹, K. Farkas², J. Banai³, L. Bene⁴, B. Gasztonyi⁵, T. Kristof⁶, L. Lakatos⁷, P. Miheller⁸, K. Palatka⁹, A. Patai¹⁰, A. Salamon¹¹, T. Szamosi³, Z. Szepes¹², E. Biro¹³, G.T. Toth¹⁴, A. Vincze¹⁵, T. Molnar², P. Lakatos¹

Created: Friday, 22 February 2019, 9:49 AM

DOP033: Severely active ulcerative colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes

Year: 2017

Source: ECCO '17 Barcelona

Authors:

Vande Casteele N.^*1,2, Jairath V.^3,4, Levesque B.^1,2, Feagan B.^3,4, Sandborn W.^1,2

Created: Wednesday, 20 February 2019, 10:36 AM

DOP033: Severely active Ulcerative Colitis is associated with high baseline infliximab clearance, reduced serum half-life and worse endoscopic outcomes

Year: 2017

Source: ECCO'17 Barcelona

Authors: Vande Casteele N.

Theraputic drug monitoring, Anti-TNF agents, Infliximab, Pharmacokinetics, Treat to target

Files: 1

DOP033: Trends in epidemiology of inﬂammatory bowel disease among Jewish Israeli adolescents: a population-based study

Year: 2018

Source: ECCO '18 Vienna

Authors:

I. Ghersin¹*, L.H. Katz², S. Daher³, R. Shamir⁴, A. Assa⁴

Created: Thursday, 21 February 2019, 9:14 AM